Valbiotis Stock

Valbiotis Net Margin

The Net Profit Margin of Valbiotis (ALVAL.PA) as of Aug 5, 2026 is -5,728.57 %. In the previous year, Net Profit Margin was -155.67 % — a change of 3,579.88% (lower).

Net Margin

-5,728.57 %

YoY

3,579.88%

Last updated:

Net Profit Margin of Valbiotis is 2026 -5,728.57 % . Net Profit Margin of Valbiotis was 2025 -155.67 % . It decreases by 3,579.88% lower compared to the previous year.

For Valbiotis, the net margin of -5,728.6% is down versus -123.8% a few years ago.

Access this data via the Eulerpool API

Valbiotis Stock analysis

What does Valbiotis do? Valbiotis SA is a French company specializing in the research and development of new and innovative treatment options based on plant-derived ingredients. The company was founded in 2014 by Sebastien Peltier, an experienced employee in the pharmaceutical industry, who wanted to search for new and effective therapeutic possibilities. Valbiotis' business model is based on identifying and utilizing new plant-derived ingredients to develop therapies that cater to market needs. The company works closely with various partners, universities, and research organizations to ensure that their products are based on the latest scientific findings. One of Valbiotis' main areas of focus is the development of products to support metabolism and metabolic health. They utilize solutions based on a plant-derived ingredient called TOTUM-63, which aims to treat and prevent risk factors such as obesity, insulin resistance, and metabolic diseases like Type 2 diabetes. Valbiotis has also established a comprehensive research department to explore further applications for their plant-derived ingredients, including cardiovascular diseases and neurodegenerative diseases like Alzheimer's. One of Valbiotis' most well-known products is TOTUM-63, a plant-derived ingredient that has positive effects on metabolism. TOTUM-63 consists of four different plant-derived ingredients and is intended to restore balance to metabolism and support the body in combating risk factors such as obesity and Type 2 diabetes. The company is currently seeking further promising applications for TOTUM-63. Valbiotis has also formed partnerships with major pharmaceutical companies such as Nestlé Health Science and Nestlé Research to fund their research and optimize the use of their plant-derived ingredients. Additionally, Valbiotis collaborates with various universities and research institutions to incorporate the latest scientific findings into their products. Overall, Valbiotis is one of the most promising companies in the pharmaceutical industry focused on plant-derived ingredients. The company has developed a wide range of products and applications and works closely with various partners to develop innovative therapy options based on plant-derived ingredients. Valbiotis is well-positioned to achieve further growth in the future and treat and prevent diseases in a new way. Valbiotis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Valbiotis stock

Net Profit Margin of Valbiotis is -5,728.57 % in 2026.

Net Profit Margin of Valbiotis changed from -155.67 % to -5,728.57 %, representing a 3,579.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Valbiotis since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Valbiotis with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

Margins — Valbiotis

All Key Metrics — Valbiotis